Contribute Try STAT+ Today

This spring, Alexandre Padilha was one of several Brazilian lawmakers who introduced a bill to permit the government to temporarily suspend any and all patents for medical products that could be used to fight Covid-19, as well as any future public health emergency declared by Brazilian authorities or the World Health Organization. The proposal arrived amid mounting angst over access to Covid-19 medical products, which has prompted a growing number of countries to consider compulsory licenses. These permit a public agency to work with a generic drug maker to copy a patented medicine without the consent of the brand-name company that owns the patent. Whether the Brazilian government will embrace the bill is uncertain. The government recently refused to sign on to a proposal from India and South Africa that urged the World Trade Organization to suspend all patents on medicines, vaccines and products to combat Covid-19. We asked Padilha about why he pushed this bill and also about his concerns over access to medicines.  

Why do you believe Brazil needs a law to issue compulsory licenses for Covid-19 medical products?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.